Aimmune Therapeutics, Inc. (AIMT) Q4 2019 Results Earnings Conference Call February 27, 2020 4:30 PM ET
Company Participants
DeDe Sheel - Vice President of Investor Relations
Eric Bjerkholt - Chief Financial Officer
Jayson Dallas - President and Chief Executive Officer
Andrew Oxtoby - Chief Commercial Officer
Conference Call Participants
Chris Raymond - Piper Sandler
Charles Duncan - Cantor Fitzgerald
Liana Moussatos - Wedbush Securities
Evan Seigerman - Credit Suisse.
Zegbeh Jallah - Roth Capital Partners
Corinne Jenkins - with Goldman Sach
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Aimmune Fourth Quarter 2019 Earnings Conference Call. At this time, all participants’ lines are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker today, DeDe Sheel, Vice President of Investor Relations. Thank you, and please go ahead, Ma’am.
DeDe Sheel
Thank you, operator. Good afternoon and thank you for joining us today to discuss Aimmune's fourth quarter and fiscal year 2019 financial results and operational highlights. Today's call is being webcast and a replay will be available on our corporate website at aimmune.com.
Joining me on the call today are Dr. Jayson Dallas, President and Chief Executive Officer; Andrew Oxtoby, Chief Commercial Officer; and Eric Bjerkholt, Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.
Before we begin, I would like to remind you that during today's call and Q&A session, we will be making forward-looking statements. These forward-looking statements include Aimmune’s expectations regarding the potential benefits of PALFORZIA, the commercial launch of PALFORZIA including the timing for speciality pharmacies to be ready to dispense PALFORZIA, timing for payors in the United States to add PALFORZIA
- Read more current AIMT analysis and news
- View all earnings call transcripts